{"url_path":"/sec/ipsc/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-059816-index.html","accession_number":"0001104659-26-059816","cik":"0001850119","ticker":"IPSC","issuer_name":"Century Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1850119/0001104659-26-059816-index.html","primary_entity_key":"0001850119","primary_entity_name":"Century Therapeutics, Inc."},"word_count":1641,"has_tables":true,"body_markdown":"Century Therapeutics, Inc._March 31, 2026\n\nhttp://www.centurytx.com/20260331#AccruedExpensesAndOtherLiabilitiesCurrenthttp://www.centurytx.com/20260331#AccruedExpensesAndOtherLiabilitiesCurrent0001850119false--12-312026Q1000000001850119us-gaap:PrivatePlacementMember2026-01-072026-01-070001850119ipsc:AtMarketOfferingMember2026-01-012026-03-310001850119ipsc:AtMarketOfferingMember2025-01-012025-03-310001850119us-gaap:RetainedEarningsMember2026-03-310001850119us-gaap:AdditionalPaidInCapitalMember2026-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001850119us-gaap:RetainedEarningsMember2025-12-310001850119us-gaap:AdditionalPaidInCapitalMember2025-12-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001850119us-gaap:RetainedEarningsMember2025-03-310001850119us-gaap:AdditionalPaidInCapitalMember2025-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001850119us-gaap:RetainedEarningsMember2024-12-310001850119us-gaap:AdditionalPaidInCapitalMember2024-12-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001850119us-gaap:CommonStockMember2026-03-310001850119us-gaap:CommonStockMember2025-12-310001850119us-gaap:CommonStockMember2025-03-310001850119us-gaap:CommonStockMember2024-12-310001850119us-gaap:EmployeeStockOptionMember2025-12-310001850119us-gaap:EmployeeStockOptionMemberipsc:IncentivePlan2021Member2026-01-012026-03-310001850119us-gaap:EmployeeStockOptionMember2026-03-310001850119ipsc:EmployeeStockPurchasePlan2021Member2026-03-310001850119ipsc:IncentivePlan2021Member2025-12-310001850119us-gaap:EmployeeStockOptionMemberipsc:IncentivePlan2021Member2021-06-170001850119ipsc:EmployeeStockPurchasePlan2021Member2021-05-310001850119us-gaap:EmployeeStockOptionMember2025-01-012025-12-310001850119us-gaap:RestrictedStockUnitsRSUMember2026-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2025-12-310001850119us-gaap:RestrictedStockUnitsRSUMemberipsc:IncentivePlan2021Member2026-01-012026-03-310001850119us-gaap:PrivatePlacementMember2026-01-092026-01-0900018501192026-01-272026-01-270001850119ipsc:DistributedBioMasterServiceAgreementMember2026-01-012026-03-310001850119ipsc:DistributedBioMasterServiceAgreementMember2025-01-012025-03-310001850119ipsc:FcdiCollaborationAgreementMember2026-01-012026-03-310001850119ipsc:FcdiCollaborationAgreementMember2025-01-012025-03-310001850119us-gaap:SoftwareDevelopmentMember2026-03-310001850119us-gaap:LeaseholdImprovementsMember2026-03-310001850119us-gaap:FurnitureAndFixturesMember2026-03-310001850119us-gaap:ConstructionInProgressMember2026-03-310001850119ipsc:LabEquipmentMember2026-03-310001850119us-gaap:SoftwareDevelopmentMember2025-12-310001850119us-gaap:LeaseholdImprovementsMember2025-12-310001850119us-gaap:FurnitureAndFixturesMember2025-12-310001850119us-gaap:ConstructionInProgressMember2025-12-310001850119ipsc:LabEquipmentMember2025-12-310001850119ipsc:SalesAgreementMember2026-01-012026-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001850119ipsc:AccountsPayableCurrentMemberipsc:DistributedBioMasterServiceAgreementMember2026-03-310001850119ipsc:AccountsPayableCurrentMemberipsc:DistributedBioMasterServiceAgreementMember2025-12-310001850119us-gaap:RetainedEarningsMember2026-01-012026-03-310001850119us-gaap:RetainedEarningsMember2025-01-012025-03-310001850119srt:MinimumMember2026-03-310001850119srt:MaximumMember2026-03-310001850119ipsc:MilestoneMember2026-03-310001850119ipsc:MilestoneMember2025-12-310001850119ipsc:MilestoneMember2025-03-310001850119ipsc:HoldbackMember2025-03-310001850119ipsc:GadetaMember2025-03-310001850119ipsc:MilestoneMember2024-12-310001850119ipsc:HoldbackMember2024-12-310001850119ipsc:GadetaMember2024-12-310001850119ipsc:TimeBasedVestingMember2026-03-310001850119ipsc:UnvestedRestrictedStockUnitWithTimeBasedVestingMember2026-01-012026-03-310001850119ipsc:TimeBasedVestingMember2026-01-012026-03-310001850119ipsc:UnvestedRestrictedStockUnitWithTimeBasedVestingMember2026-03-310001850119ipsc:Next2OfParticipatingEmployeeContributionsMember2026-01-012026-03-310001850119ipsc:First3OfParticipatingEmployeeContributionsMember2026-01-012026-03-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2026-03-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2026-03-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2025-12-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2025-12-3100018501192025-01-012025-12-310001850119ipsc:OptionRightsMemberipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2025-01-012025-03-310001850119us-gaap:EmployeeStockMemberipsc:IncentivePlan2021Member2026-03-310001850119ipsc:IncentivePlan2021Member2026-03-310001850119ipsc:CommonWarrantsAccompaniedWithPreFundedWarrantsMemberus-gaap:PrivatePlacementMember2026-01-070001850119ipsc:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2026-01-070001850119ipsc:CommonWarrantsMemberus-gaap:PrivatePlacementMember2026-01-0700018501192025-03-3100018501192024-12-310001850119ipsc:MilestoneMemberus-gaap:MeasurementInputDiscountRateMember2026-03-310001850119ipsc:MilestoneMemberipsc:MeasurementInputMilestonePaymentProbabilityAdjustedValueMember2026-03-310001850119ipsc:MilestoneMemberipsc:MeasurementInputDiscountPeriodMember2026-03-310001850119ipsc:MilestoneMemberus-gaap:MeasurementInputDiscountRateMember2025-12-310001850119ipsc:MilestoneMemberipsc:MeasurementInputMilestonePaymentProbabilityAdjustedValueMember2025-12-310001850119ipsc:MilestoneMemberipsc:MeasurementInputDiscountPeriodMember2025-12-310001850119us-gaap:FairValueInputsLevel3Member2026-03-310001850119us-gaap:FairValueInputsLevel3Member2025-12-310001850119ipsc:MilestoneMember2026-01-012026-03-310001850119ipsc:MilestoneMember2025-01-012025-03-310001850119ipsc:HoldbackMember2025-01-012025-03-310001850119us-gaap:USTreasurySecuritiesMember2026-03-310001850119us-gaap:CorporateBondSecuritiesMember2026-03-310001850119us-gaap:USTreasurySecuritiesMember2025-12-310001850119us-gaap:CorporateBondSecuritiesMember2025-12-310001850119us-gaap:FairValueInputsLevel2Member2026-03-310001850119us-gaap:FairValueInputsLevel1Member2026-03-310001850119us-gaap:FairValueInputsLevel2Member2025-12-310001850119us-gaap:FairValueInputsLevel1Member2025-12-3100018501192025-07-012025-09-300001850119us-gaap:WarrantMember2026-01-012026-03-310001850119us-gaap:StockOptionMember2026-01-012026-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001850119us-gaap:WarrantMember2025-01-012025-03-310001850119us-gaap:StockOptionMember2025-01-012025-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001850119ipsc:EarlyExercisedStockOptionsSubjectToFutureVestingMember2025-01-012025-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001850119us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001850119us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001850119us-gaap:EmployeeStockMember2026-01-012026-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001850119us-gaap:RestrictedStockMember2025-01-012025-03-310001850119us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001850119us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001850119us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001850119us-gaap:EmployeeStockMember2025-01-012025-03-310001850119us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001850119us-gaap:CommonStockMember2025-01-012025-03-310001850119us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001850119us-gaap:CommonStockMember2026-01-012026-03-310001850119us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001850119ipsc:EmployeeStockOptionsAndRestrictedStockUnitsMemberipsc:IncentivePlan2021Member2026-03-310001850119ipsc:EmployeeStockPurchasePlan2021Member2026-01-012026-03-310001850119ipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2026-03-310001850119ipsc:CatalentDusseldorfGmbhLicenseAgreementMember2026-03-310001850119ipsc:CatalentDusseldorfGmbhLicenseAgreementMember2026-01-012026-03-310001850119ipsc:CatalentDusseldorfGmbhLicenseAgreementMember2025-01-012025-03-310001850119ipsc:IncentivePlan2021Member2026-01-012026-03-310001850119ipsc:EmployeeStockPurchasePlan2021Member2022-01-012022-12-310001850119ipsc:SingleReportableSegmentMember2026-01-012026-03-310001850119ipsc:SingleReportableSegmentMember2025-01-012025-03-310001850119ipsc:IcellInc.SublicenseAgreementMember2020-03-310001850119ipsc:CladeTherapeuticsInc.Member2024-04-110001850119srt:MaximumMemberipsc:IcellInc.SublicenseAgreementMember2020-03-310001850119ipsc:DistributedBioMasterServiceAgreementMember2019-07-240001850119ipsc:IcellInc.SublicenseAgreementMember2026-03-310001850119ipsc:DistributedBioMasterServiceAgreementMember2026-03-310001850119ipsc:IcellInc.SublicenseAgreementMember2025-03-310001850119ipsc:FcdiCollaborationAgreementMemberipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2022-01-310001850119us-gaap:PrivatePlacementMember2026-01-0700018501192025-01-012025-03-3100018501192026-03-3100018501192025-12-310001850119ipsc:GregoryRussottiMemberipsc:TradingPlanTwoMember2026-03-310001850119ipsc:GregoryRussottiMemberipsc:TradingPlanOneMember2026-03-310001850119ipsc:GregoryRussottiMemberipsc:TradingPlanOneMember2026-01-012026-03-310001850119ipsc:GregoryRussottiMemberipsc:TradingPlanTwoMember2026-01-012026-03-310001850119ipsc:GregoryRussottiMember2026-01-012026-03-3100018501192026-05-0100018501192026-01-012026-03-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureipsc:Yipsc:itemipsc:segment\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, DC 20549**\n\n**FORM ****10-Q**\n\n**(Mark One)**\n\n​\n\n​\n\n**☒**\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**For the quarterly period ended****March 31, 2026**\n\n**OR**\n\n​\n\n​\n\n**☐**\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**For the transition period from _______ to _______                      **\n\n**Commission File Number:****001-40498**\n\n​\n\n**Century Therapeutics, Inc.**\n\n**(Exact Name of Registrant as Specified in its Charter)**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Delaware**\n\n  ​ ​ ​\n\n**84-2040295**\n\n**(State or other jurisdiction of********incorporation or organization)**\n\n​\n\n**(I.R.S. Employer********Identification No.)**\n\n**25 N 38**th**Street, 11**th**Floor********Philadelphia****,****Pennsylvania********(Address of principal executive offices)**\n\n​\n\n**19104********(Zip Code)**\n\n​\n\n**(****267****)****817-5790**\n\n**(Registrant’s telephone number, including area code)**\n\n**Not applicable**\n\n**(Former name, former address and former fiscal year, if changed since last report)**\n\n​\n\n​\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Title of each class**\n\n**  ​ ​ ​**\n\n**Trading********Symbol(s)**\n\n**  ​ ​ ​**\n\n**Name of each exchange on which registered**\n\nCommon Stock, $0.0001 par value per share\n\n​\n\nIPSC\n\n​\n\nThe Nasdaq Capital Market\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\n​\n\n​\n\nLarge accelerated filer          ☐\n\nAccelerated filer                  ☐\n\nNon-accelerated filer              ☒\n\nSmaller reporting company ☒\n\nEmerging growth company    ☒\n\n​\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒\n\nAs of May 1, 2026 the registrant had 180,354,809 shares of common stock, $0.0001 par value per share, outstanding.\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\n**Table of Contents**\n\n \n\n**Page**\n\n[**PART I.**](#PARTIFINANCIALINFORMATION_835812)\n\n[**FINANCIAL INFORMATION**](#PARTIFINANCIALINFORMATION_835812)\n\n5\n\n[Item 1.](#Item1FinancialStatements_257227)\n\n[Unaudited Consolidated Financial Statements:](#Item1FinancialStatements_257227)\n\n5\n\n​\n\n[Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 2025](#Consolidatedbalancesheets_453664)\n\n5\n\n​\n\n[Consolidated Statements of Operations and Comprehensive Income (Loss) for the three months ended March 31, 2026 and 2025 (unaudited)](#Consolidatedstatementsofoperationsandcom)\n\n6\n\n​\n\n[Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2026 and 2025 (unaudited)](#Consolidatedstatementsofchangesinconvert)\n\n7\n\n​\n\n[Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025 (unaudited)](#CONDENSEDSTATEMENTOFCASHFLOWS_471502)\n\n8\n\n​\n\n[Notes to Unaudited Consolidated Financial Statements](#NOTESTOFINANCIALSTATEMENTS5_641597)\n\n9\n\n[Item 2.](#Managementsdiscussionandanalysisoffinanc)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Managementsdiscussionandanalysisoffinanc)\n\n27\n\n[Item 3.](#Item3QuantitativeandQualitativeDisclosur)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n39\n\n[Item 4.](#Item4ControlsandProcedures_438957)\n\n[Controls and Procedures](#Item4ControlsandProcedures_438957)\n\n40\n\n​\n\n​\n\n​\n\n[**PART II.**](#PARTIIOTHERINFORMATION_986762)\n\n[**OTHER INFORMATION**](#PARTIIOTHERINFORMATION_986762)\n\n41\n\n[Item 1.](#Item1LegalProceedings_566056)\n\n[Legal Proceedings](#Item1LegalProceedings_566056)\n\n41\n\n[Item 1A.](#Item_1A_Risk_Factors)\n\n[Risk Factors](#Item_1A_Risk_Factors)\n\n41\n\n[Item 2.](#_Item_2._Unregistered)\n\n[Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities](#Item2UnregisteredSalesofEquitySecurities)\n\n41\n\n[Item 3.](#Item3DefaultsUponSeniorSecurities_4467)\n\n[Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_4467)\n\n41\n\n[Item 4.](#Item4MineSafetyDisclosures_830481)\n\n[Mine Safety Disclosures](#Item4MineSafetyDisclosures_830481)\n\n41\n\n[Item 5.](#Item5OtherInformation_669179)\n\n[Other Information](#Item5OtherInformation_669179)\n\n41\n\n[Item 6.](#Item6Exhibits_9962)\n\n[Exhibits](#Item6Exhibits_9962)\n\n43\n\n[Signatures](#Signatures_894745)\n\n44\n\n​\n\n​\n\n​\n\n​\n\n2\n\n[Table of Contents](#TOC)\n\n​\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nThis Quarterly Report on Form 10-Q and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q or the documents incorporated by reference herein regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would,” “could,” “should,” “potential,” “seek,” “evaluate,” “pursue,” “continue,” “design,” “impact,” “affect,” “forecast,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated.\n\nThe forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:\n\n●our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;\n\n●the early preclinical and clinical nature of our business and our ability to successfully advance our current and future product candidates, through development activities, preclinical studies, and clinical trials;\n\n●our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;\n\n●the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing;\n\n●the novelty of our approach to immuno-oncology and autoimmune treatments, utilizing iPSC-derived immune cells and islet cells, and the challenges we will face due to the novel nature of such technology;\n\n●the success of competing therapies that are or may become available;\n\n●the initiation, progress, success, cost, and timing of our development activities, preclinical studies and clinical trials;\n\n●the timing of future investigational new drug (“IND”), applications and the likelihood of, and our ability to obtain and maintain, regulatory clearance of IND applications for our product candidates;\n\n●the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;\n\n●the performance of third parties in connection with the development of our product candidates, including third parties conducting our current and future clinical trials as well as third-party suppliers and manufacturers;\n\n●our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise;\n\n3\n\n[Table of Contents](#TOC)\n\n●the public opinion and scrutiny of cell-based immuno-oncology and autoimmune therapies and its potential impact on public perception of our company and product candidates;\n\n●our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;\n\n●the size and growth of the potential markets for our product candidates and our ability to serve those markets;\n\n●regulatory developments and approval pathways in the United States and foreign countries for our product candidates;\n\n●the potential scope and value of our intellectual property and proprietary rights;\n\n●our ability, and the ability of our licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties;\n\n●our ability to recruit and retain key members of management and other clinical and scientific personnel;\n\n●the volatility of capital markets and other macroeconomic factors, including due to inflationary pressures, banking instability, global health crises, geopolitical tensions or the outbreak of hostilities or war;\n\n●developments relating to our competitors and our industry; and\n\n●other risks and uncertainties, including those described or incorporated by reference under the caption “Risk Factors” in this Quarterly Report on Form 10-Q.\n\nWe have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled “Risk Factors” set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q, the section titled “Risk Factors” set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 and the section titled “Risk Factors” set forth in Part II, Item 1A of our subsequent Quarterly Reports on Form 10-Q for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements.\n\nFurthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.\n\nYou should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We intend the forward-looking statements contained in this Quarterly Report on Form 10-Q to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).\n\n4\n\n[Table of Contents](#TOC)\n\n**PART I—FINANCIAL INFORMATION**"}